Blood tests could predict who benefits from magic mushroom therapy
NCT ID NCT07164755
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study looks at blood samples from 46 people with treatment-resistant depression who took psilocybin in a previous trial. Researchers will measure inflammation markers (cytokines) to see if they are linked to how well the treatment worked. The goal is to understand if inflammation levels can help predict who will benefit most from psilocybin therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION - MAJOR DEPRESSIVE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
King's College London Institute of Psychiatry, Psychology and Neuroscience
London, SE5 8AF, United Kingdom
Conditions
Explore the condition pages connected to this study.